Literature DB >> 16236613

Tumor-infiltrating cells as a prognostic factor in Hodgkin's lymphoma: a quantitative tissue microarray study in a large retrospective cohort of 267 patients.

Tomás Alvaro-Naranjo1, Marylène Lejeune, Maria T Salvadó-Usach, Ramón Bosch-Príncep, Gemma Reverter-Branchat, Joaquín Jaén-Martínez, Lluis E Pons-Ferré.   

Abstract

The present study aimed to describe the general tissular composition of the immune infiltrate observed in Hodgkin's lymphoma (HL) and its possible relationship with clinical and survival prognostic factors. In this retrospective study of 267 HL patients, the relative proportions of infiltrating T lymphocytes (CD4+, CD8+), natural killer cells (CD 56+, CD 57+), cytotoxic cells (Granzyme B+, TIA-1+) and dendritic cells (CD 21+, S-100+) were quantified immunohistochemically with tissue microarray technology. Our results confirm the predominance of CD4 + T lymphocytes in the background of tumoral cells, in addition to a high number of cytotoxic lymphocytes (CD8, CD 57 and TIA-1). Patients with low numbers of infiltrating CD8, CD 56, CD 57+cells and high numbers of Granzyme B and TIA-1+cells presented a significantly unfavourable clinical course (presence of leukocytosis, B symptoms, advanced clinical stage (III/IV), non-responding patients). A reduced infiltration of CD4+T lymphocytes was related with the presence of Epstein - Barr virus. Significantly longer survival times were observed in patients with a high level of infiltrating CD 57, as well as a low level of Granzyme B and TIA-1+cells (log-rank test). When evaluated in a multivariate model, high levels of infiltrating TIA-1 and Granzyme B+cells were shown to be independent prognostic factors that negatively influenced overall survival. The presence of TIA-1+cells was found to be the only unfavorable prognostic factor of event-free survival and disease-free survival. The overall detection of tumor-infiltrating cells in HL confirms the importance of cytotoxic T lymphocyte infiltration (Granzyme B and TIA-1+cells) in these patients. Independently of the classical clinical and pathological features, these cells appear to be an unfavourable prognostic factor in HL and, more particularly, the presence of cytotoxic TIA-1+cells.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16236613     DOI: 10.1080/10428190500220654

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  38 in total

1.  Peripheral blood lymphocyte/monocyte ratio at diagnosis and survival in classical Hodgkin's lymphoma.

Authors:  Luis F Porrata; Kay Ristow; Joseph P Colgan; Thomas M Habermann; Thomas E Witzig; David J Inwards; Stephen M Ansell; Ivana N Micallef; Patrick B Johnston; Grzegorz S Nowakowski; Carrie Thompson; Svetomir N Markovic
Journal:  Haematologica       Date:  2011-10-11       Impact factor: 9.941

2.  JPEG2000 for automated quantification of immunohistochemically stained cell nuclei: a comparative study with standard JPEG format.

Authors:  Marylène Lejeune; Carlos López; Ramón Bosch; Anna Korzyńska; Maria-Teresa Salvadó; Marcial García-Rojo; Urszula Neuman; Łukasz Witkowski; Jordi Baucells; Joaquín Jaén
Journal:  Virchows Arch       Date:  2010-11-18       Impact factor: 4.064

Review 3.  The secret ally: immunostimulation by anticancer drugs.

Authors:  Lorenzo Galluzzi; Laura Senovilla; Laurence Zitvogel; Guido Kroemer
Journal:  Nat Rev Drug Discov       Date:  2012-02-03       Impact factor: 84.694

4.  Automated quantification of nuclear immunohistochemical markers with different complexity.

Authors:  Carlos López; Marylène Lejeune; María Teresa Salvadó; Patricia Escrivà; Ramón Bosch; Lluis E Pons; Tomás Alvaro; Jordi Roig; Xavier Cugat; Jordi Baucells; Joaquín Jaén
Journal:  Histochem Cell Biol       Date:  2008-01-03       Impact factor: 4.304

5.  Breast cancer lung metastasis requires expression of chemokine receptor CCR4 and regulatory T cells.

Authors:  Purevdorj B Olkhanud; Dolgor Baatar; Monica Bodogai; Fran Hakim; Ronald Gress; Robin L Anderson; Jie Deng; Mai Xu; Susanne Briest; Arya Biragyn
Journal:  Cancer Res       Date:  2009-06-30       Impact factor: 12.701

6.  Roundness variation in JPEG images affects the automated process of nuclear immunohistochemical quantification: correction with a linear regression model.

Authors:  Carlos López; Joaquín Jaén Martinez; Marylène Lejeune; Patricia Escrivà; Maria T Salvadó; Lluis E Pons; Tomás Alvaro; Jordi Baucells; Marcial García-Rojo; Xavier Cugat; Ramón Bosch
Journal:  Histochem Cell Biol       Date:  2009-08-04       Impact factor: 4.304

7.  Effects of image compression on automatic count of immunohistochemically stained nuclei in digital images.

Authors:  Carlos López; Marylène Lejeune; Patricia Escrivà; Ramón Bosch; Maria Teresa Salvadó; Lluis E Pons; Jordi Baucells; Xavier Cugat; Tomás Alvaro; Joaquín Jaén
Journal:  J Am Med Inform Assoc       Date:  2008-08-28       Impact factor: 4.497

8.  Quantification of diverse subcellular immunohistochemical markers with clinicobiological relevancies: validation of a new computer-assisted image analysis procedure.

Authors:  Marylène Lejeune; Joaquín Jaén; Lluis Pons; Carlos López; Maria-Teresa Salvadó; Ramón Bosch; Marcial García; Patricia Escrivà; Jordi Baucells; Xavier Cugat; Tomás Alvaro
Journal:  J Anat       Date:  2008-06       Impact factor: 2.610

9.  Prognostic Analysis of Absolute Lymphocyte and Monocyte Counts after Autologous Stem Cell Transplantation in Children, Adolescents, and Young Adults with Refractory or Relapsed Hodgkin Lymphoma.

Authors:  Jorge Galvez-Silva; Ossama M Maher; Minjeong Park; Diane Liu; Fiorela Hernandez; Priti Tewari; Yago Nieto
Journal:  Biol Blood Marrow Transplant       Date:  2017-04-20       Impact factor: 5.742

10.  Prognostic significance of new immunohistochemical markers in refractory classical Hodgkin lymphoma: a study of 59 cases.

Authors:  Danielle Canioni; Bénédicte Deau-Fischer; Pierre Taupin; Vincent Ribrag; Richard Delarue; Jacques Bosq; Marie-Thérèse Rubio; Damien Roux; Viorel Vasiliu; Bruno Varet; Nicole Brousse; Olivier Hermine
Journal:  PLoS One       Date:  2009-07-22       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.